In 2005, two seminal papers were published demonstrating that breast cancer cells with siRNA depletion of BRCA1 or BRCA2 were exquisitely sensitive to the PARP inhibitor NU1025 [15,16]. Here, BRCA1 is linked to breast carcinoma.